Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis

Catherine A. Roca, Tung Ping Su, Sarah Elpern, Henry McFarland, David R. Rubinow

Research output: Contribution to journalArticle

Abstract

Background: Cerebrospinal fluid (CSF) somatostatin (SS) levels have been shown to be decreased in multiple sclerosis (MS) during relapse as well as in disorders characterized by depression or cognitive impairment. Since MS is often associated with depression and cognitive impairment, we examined both the effect of course of illness on CSF SS as well as the variance in SS attributable to associated features (e.g., depression or cognitive impairment). Methods: Fifteen patients with chronic progressive MS participating in a 2-year cyclosporine trial underwent lumbar punctures for CSF SS at baseline and at 12 and 24 months. Additionally, patients were evaluated by neuropsychological testing, and physical disability and mood ratings. Baseline CSF SS levels were also obtained in a group of control subjects (n = 10). Results: At baseline, CSF SS levels were lower in MS patients than control subjects (p <.001). Decreaed CSF SS at 24 months was correlated with decreased cognitive performance on several measures and was best and significantly predicted by cognitive deterioration at 24 months. Conclusions: Our data support those from previous studies that found lower levels of CSF SS in MS during relapse and suggest that changes in CSF SS are related to the process responsible for diminished cognitive function in MS. Copyright (C) 1999 Society of Biological Psychiatry.

Original languageEnglish (US)
Pages (from-to)551-556
Number of pages6
JournalBiological Psychiatry
Volume46
Issue number4
DOIs
StatePublished - Aug 15 1999
Externally publishedYes

Fingerprint

Somatostatin
Cognition
Multiple Sclerosis
Cerebrospinal Fluid
Depression
Chronic Progressive Multiple Sclerosis
Recurrence
Spinal Puncture
Cyclosporine
Control Groups

Keywords

  • Cerebrospinal fluid
  • Mood
  • Multiple sclerosis
  • Neuropsychological testing
  • Somatostatin

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Roca, C. A., Su, T. P., Elpern, S., McFarland, H., & Rubinow, D. R. (1999). Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis. Biological Psychiatry, 46(4), 551-556. https://doi.org/10.1016/S0006-3223(99)00006-2

Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis. / Roca, Catherine A.; Su, Tung Ping; Elpern, Sarah; McFarland, Henry; Rubinow, David R.

In: Biological Psychiatry, Vol. 46, No. 4, 15.08.1999, p. 551-556.

Research output: Contribution to journalArticle

Roca, CA, Su, TP, Elpern, S, McFarland, H & Rubinow, DR 1999, 'Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis', Biological Psychiatry, vol. 46, no. 4, pp. 551-556. https://doi.org/10.1016/S0006-3223(99)00006-2
Roca, Catherine A. ; Su, Tung Ping ; Elpern, Sarah ; McFarland, Henry ; Rubinow, David R. / Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis. In: Biological Psychiatry. 1999 ; Vol. 46, No. 4. pp. 551-556.
@article{d03146697b8e4bc7a328a369544314bc,
title = "Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis",
abstract = "Background: Cerebrospinal fluid (CSF) somatostatin (SS) levels have been shown to be decreased in multiple sclerosis (MS) during relapse as well as in disorders characterized by depression or cognitive impairment. Since MS is often associated with depression and cognitive impairment, we examined both the effect of course of illness on CSF SS as well as the variance in SS attributable to associated features (e.g., depression or cognitive impairment). Methods: Fifteen patients with chronic progressive MS participating in a 2-year cyclosporine trial underwent lumbar punctures for CSF SS at baseline and at 12 and 24 months. Additionally, patients were evaluated by neuropsychological testing, and physical disability and mood ratings. Baseline CSF SS levels were also obtained in a group of control subjects (n = 10). Results: At baseline, CSF SS levels were lower in MS patients than control subjects (p <.001). Decreaed CSF SS at 24 months was correlated with decreased cognitive performance on several measures and was best and significantly predicted by cognitive deterioration at 24 months. Conclusions: Our data support those from previous studies that found lower levels of CSF SS in MS during relapse and suggest that changes in CSF SS are related to the process responsible for diminished cognitive function in MS. Copyright (C) 1999 Society of Biological Psychiatry.",
keywords = "Cerebrospinal fluid, Mood, Multiple sclerosis, Neuropsychological testing, Somatostatin",
author = "Roca, {Catherine A.} and Su, {Tung Ping} and Sarah Elpern and Henry McFarland and Rubinow, {David R.}",
year = "1999",
month = "8",
day = "15",
doi = "10.1016/S0006-3223(99)00006-2",
language = "English (US)",
volume = "46",
pages = "551--556",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Cerebrospinal fluid somatostatin, mood, and cognition in multiple sclerosis

AU - Roca, Catherine A.

AU - Su, Tung Ping

AU - Elpern, Sarah

AU - McFarland, Henry

AU - Rubinow, David R.

PY - 1999/8/15

Y1 - 1999/8/15

N2 - Background: Cerebrospinal fluid (CSF) somatostatin (SS) levels have been shown to be decreased in multiple sclerosis (MS) during relapse as well as in disorders characterized by depression or cognitive impairment. Since MS is often associated with depression and cognitive impairment, we examined both the effect of course of illness on CSF SS as well as the variance in SS attributable to associated features (e.g., depression or cognitive impairment). Methods: Fifteen patients with chronic progressive MS participating in a 2-year cyclosporine trial underwent lumbar punctures for CSF SS at baseline and at 12 and 24 months. Additionally, patients were evaluated by neuropsychological testing, and physical disability and mood ratings. Baseline CSF SS levels were also obtained in a group of control subjects (n = 10). Results: At baseline, CSF SS levels were lower in MS patients than control subjects (p <.001). Decreaed CSF SS at 24 months was correlated with decreased cognitive performance on several measures and was best and significantly predicted by cognitive deterioration at 24 months. Conclusions: Our data support those from previous studies that found lower levels of CSF SS in MS during relapse and suggest that changes in CSF SS are related to the process responsible for diminished cognitive function in MS. Copyright (C) 1999 Society of Biological Psychiatry.

AB - Background: Cerebrospinal fluid (CSF) somatostatin (SS) levels have been shown to be decreased in multiple sclerosis (MS) during relapse as well as in disorders characterized by depression or cognitive impairment. Since MS is often associated with depression and cognitive impairment, we examined both the effect of course of illness on CSF SS as well as the variance in SS attributable to associated features (e.g., depression or cognitive impairment). Methods: Fifteen patients with chronic progressive MS participating in a 2-year cyclosporine trial underwent lumbar punctures for CSF SS at baseline and at 12 and 24 months. Additionally, patients were evaluated by neuropsychological testing, and physical disability and mood ratings. Baseline CSF SS levels were also obtained in a group of control subjects (n = 10). Results: At baseline, CSF SS levels were lower in MS patients than control subjects (p <.001). Decreaed CSF SS at 24 months was correlated with decreased cognitive performance on several measures and was best and significantly predicted by cognitive deterioration at 24 months. Conclusions: Our data support those from previous studies that found lower levels of CSF SS in MS during relapse and suggest that changes in CSF SS are related to the process responsible for diminished cognitive function in MS. Copyright (C) 1999 Society of Biological Psychiatry.

KW - Cerebrospinal fluid

KW - Mood

KW - Multiple sclerosis

KW - Neuropsychological testing

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0032786425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032786425&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(99)00006-2

DO - 10.1016/S0006-3223(99)00006-2

M3 - Article

VL - 46

SP - 551

EP - 556

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 4

ER -